عرض بسيط للتسجيلة

المؤلفVranic, Semir
المؤلفGatalica, Zoran
تاريخ الإتاحة2023-01-22T09:53:42Z
تاريخ النشر2022
اسم المنشورBosnian Journal of Basic Medical Sciences
المصدرScopus
معرّف المصادر الموحدhttp://dx.doi.org/10.17305/bjbms.2021.6100
معرّف المصادر الموحدhttp://hdl.handle.net/10576/38677
الملخصAntibody-drug conjugates represent a new class of highly potent antineoplastic drugs built by attaching a small molecule of an anticancer drug (payload) or another therapeutic agent to an antibody recognizing an epitope on the targeted cells. Trophoblast cell-surface antigen-2 (Trop-2) was originally described in trophoblasts and fetal tissues, but subsequently its overexpression has been demonstrated in various solid malignan-cies. Sacituzumab govitecan (SG), a conjugate of anti-Trop-2 antibody and SN-38 payload (an active metabolite of irinotecan), is the first in the class that has been clinically validated and approved by the Food and Drug Administration for the treatment of metastatic triple-negative breast (2020) and urothelial carcinomas (2021). In the current review, we summarize and critically appraise the most recent advances with regard to SG, emphasizing the predictive biomarker analysis.
اللغةen
الناشرAssociation of Basic Medical Sciences of FBIH
الموضوعAntibody-drug conjugates
Breast cancer
Predictive biomarkers
Sacituzumab govitecan
Trophoblast cell-surface antigen-2
Urothelial cancer
العنوانTrop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
النوعArticle
الصفحات14-21
رقم العدد1
رقم المجلد22
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة